Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations, expanding the addressable patient population by offering one solution for many mutations. Our mission: defeat cancer resistance and provide people living with cancer the opportunity to experience longer, healthier and more active lives. We are advancing two potent, brain-penetrant clinical-stage programs: BDTX-1535, a fourth-generation EGFR inhibitor targeting non-small cell lung cancer (NSCLC) and glioblastoma (GBM) and BDTX-4933, a RAF inhibitor targeting KRAS, NRAS and BRAF alterations in NSCLC and other solid tumors.
Company Details
- Employees
- 35
- Founded
- -
- Address
- One Main Street,
- Phone
- 617-417-5868
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- bdtherapeutics.com
- HQ
- Cambridge, MA
Black Diamond Therapeutics Questions
Black Diamond Therapeutics's helpline number is 617-417-5868
Black Diamond Therapeutics's website is bdtherapeutics.com
Black Diamond Therapeutics's LinkedIn profile is https://www.linkedin.com/company/black-diamond-therapeutics
Black Diamond Therapeutics has
35 employees.
View email and phone details for 35
employees at Black Diamond Therapeutics.
Black Diamond Therapeutics's industry is
Biotechnology Research
Black Diamond Therapeutics's top competitors are
Cimeio Therapeutics,
Bright Peak Therapeutics,
Servier,
Alentis Therapeutics,
Servier Pharmaceuticals,
Monte Rosa Therapeutics,
Ridgeline Discovery,
Araris Biotech Ag,
Black Diamond Networks,
Dren Bio, Inc..
Black Diamond Therapeutics's support email address is info@bdtherapeutics.com
Black Diamond Therapeutics's categories are Biotechnology Research
Black Diamond Therapeutics's founding year is 2017
